AMGEN International Prize: The history and future of renoprotection

Kidney International

Volumn 64, Issue 4, 2003, Pages 1163-1168

  Brenner, Barry M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; OMAPATRILAT; RAMIPRIL; TRANDOLAPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; GLOMERULUS CAPILLARY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL PRACTICE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RENOVASCULAR HYPERTENSION; SIDE EFFECT;

EID: 0141563596     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00249.x     Document Type: Conference Paper

References (42)

1. BRENNER BM, TROY JL, DAUGHARTY TM: The dynamics of glomerular ultrafiltration in the rat. J Clin Invest 50:1776-1780, 1971
2. HOSTETTER TH, OLSON JL, RENNKE HG, et al: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
3. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
4. BRENNER BM: Nephron adaptation to renal injury or ablation. Am J Physiol 249:F324-F337, 1985
5. BRENNER BM, GARCIA DL, ANDERSON S: Glomeruli and blood pressure. Less of one, more the other? Am J Hypert 1:335-347, 1988
6. BRENNER BM, CHERTOW GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23:171-175, 1994
7. NELSON RG: Intrauterine determinants of diabetic kidney disease in disadvantaged populations. Kidney Int 63(Suppl 83):S13-S16, 2003
8. KELLER G, ZIMMER G, MALL G, et al: Nephron number in patients with primary hypertension. N Engl J Med 348:101-108, 2003
9. HUGHSON M, FARRIS AB, DOUGLAS-DENTON R, et al: Glomerular number and size in autopsied kidneys: The relationship to birth weight. Kidney Int 63:2113-2122, 2003
10. ZATZ R, MEYER TW, RENNKE HG, BRENNER BM: Predominance of hemodynamics rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
11. MYERS BD, DEEN WM, BRENNER BM: Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37:101-110, 1975
12. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
13. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
14. EDDY AA, GIACHELLI CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546-1557, 1995
15. GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98:1063-1068, 1996
16. ABBATE M, ZOJA C, CORNA D, et al: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstital inflammation. J Am Soc Nephrol 9:1213-1224, 1998
17. RUIZ-ORTEGA M, LORENZO O, SUZUKI Y, et al: Pro-inflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321-329, 2001
18. KLAHR S, LEVEY AS, BECK GL, et al: The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease study group. N Engl J Med 330:877-884, 1994
19. LEVEY AS, ADLER S, GREENE T, et al: Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 7:2616-2626, 1996
20. LEVEY AS, ADLER S, CAGGIULA AW, et al: Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 27:652-663, 1996
21. PEDRINI MT, LEVEY AS, LAU J, et al: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:627-632, 1996
22. ZATZ R, DUNN BR, MEYER TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
23. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
24. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
25. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
26. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
27. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
28. RUGGENENTI P, PERNA A, GHERARDI G, et al, FOR THE GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA (GISEN): Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Ramipril efficacy in nephrology. Lancet 352:1252-1256, 1998
29. RUGGENENTI P, PERNA A, BENINI R, et al, fOR THE GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA (GISEN): In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc Nephrol 10:997-1006, 1999
30. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
31. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
32. WRIGHT JT: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421-2431, 2002
33. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
34. DAHLÖF B, DEVEREUX R, SJELDSEN S, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003, 2002
35. JACOBSEN P, ANDERSEN S, ROSSING K, et al: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63:1874-1880, 2003
36. SEGURA J, PRAGA M, CAMPO C, et al: Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J RAAS 4:43-47, 2003
37. CAMPBELL R, SANGALLI F, PERTICUCCI E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094-1103, 2003
38. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
39. TAAL MW, BRENNER BM: Combination ACEI and ARB therapy: Additional benefit in renoprotection? Curr Opin Nephrol Hypertens 11:377-382, 2002
40. TAAL MW, NENOV VD, WONG W, et al: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059, 2001
41. CHOBANIAN A, BAKRIS G, BLACK H, et al: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 289:2560-2574, 2003
42. WALD NJ, LAW MR: A strategy to reduce cardiovascular disease by more than 80%. Br Med J 326:1419-1424, 2003